Kelowna, British Columbia — May 5, 2026 — Leads & Copy — Lexaria Bioscience Corp. (NASDAQ: LEXX) is providing an update on Human Pilot Study #7 (GLP-1-H26-7), which will evaluate two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo Nordisk’s commercially available Wegovy tablets.

Submissions have been made to request ethics approval from an independent review board. Final laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles have been completed, with third-party independent lab quality-control testing underway. Lexaria anticipates that ethics approval, completion of QC testing, and packaging of the qualified test articles will occur by early June.

The study is planned to be a five-week parallel group design, investigating three separate arms to assess safety, tolerability, and pharmacokinetic properties. The study will compare salcaprozate sodium (“SNAC”)-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy tablets under fasted pre-dose conditions.

Lexaria hopes to preserve the superior safety and tolerability profiles, as evidenced in previous Lexaria GLP-1 studies such as Human Study #4 (GLP-1-H25-4), combined with PK performance that matches or exceeds that of the commercial oral tablet, as also evidenced in previous Lexaria SNAC-inclusive DHT-sema studies such as Human Studies #1 and #2 (GLP-1-H24-1and GLP-1-H24-2).

The results are expected to be carefully reviewed by the pharmaceutical industry to evaluate the possibility of commercial relationships focused on Lexaria’s DehydraTECH technology.

The study explores several new DehydraTECH enhancements not previously evaluated, including the use of an oral tablet DHT-sema composition, as opposed to only capsule compositions used in previous GLP-1 studies. Lexaria has attempted to mimic and integrate certain properties of the Rybelsus/Wegovy tablet delivery modality into its DHT-sema tablets, which it believes may increase the likelihood of commercial pharmaceutical relationships.

Both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, marking the first time these formulations are evaluated over a multi-dose, multi-week period in humans. The five-week dosing duration is expected to be long enough to reach steady-state. Earlier DHT-sema human pilot studies GLP-1-H24-1 and GLP-1-H24-2, conducted in 2024 and 2025, also used SNAC but were limited by single-dose study designs.

Lexaria will update its stakeholders once the Pre-Dosing Tasks have been achieved and anticipates dosing to begin in mid-June. The Study is fully funded from existing corporate resources.

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.

Source: Lexaria Bioscience Corp.